Autoimmune MRL mice express high-affinity IgG2b monoclonal autoantibodies to heparin

Clinical Immunology and Immunopathology

Volumn 81, Issue 1, 1996, Pages 62-67

  Fillit, H ^a,b   Edstrom, W ^a   Yang, C P ^a   Moran, T ^a   Dimitriu Bona, A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NYLCare Health Plans Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN;

ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ETIOLOGY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0030272484     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0158     Document Type: Article

References (35)

1. 1. Lindahl, U., and Kjellan, L., Heparin or heparan sulfate - what is the difference? Thromb. Haemostas. 66, 44-48, 1991.
2. 2. David, G., Structural and functional diversity of the heparan sulfate proteoglycans. Adv. Exp. Med. Biol. 313, 69-78, 1992.
3. 3. Ishihara, M., Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2. Glycobiology 4, 817, 1994.
4. 4. Choay, J., Petitou, M., Lormeau, J. C., Sinav, P., Casu, B., and Gatti, G., Structure activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun. 116, 492-499, 1983.
5. 5. Wight, T. N., Cell biology of arterial proteoglycans. Arteriosclerosis 9, 1-20, 1989.
6. 6. Nader, H. B., Dietrich, C. P., Buonassisi, V., and Colburn, P., Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc. Natl. Acad. Sci. USA 84, 3565-3569, 1987.
7. 7. Marcum, J. A., Atha, D. H., Fritze, L. M. S., Nawroth, P., Stern, D., and Rosenberg, R. D. R., Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J. Biol. Chem. 261, 7507-7517, 1986.
8. 8. Shibata, S., Harpel, P. C., Gharavi, A., Rand, J., and Fillit, H., Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit the formation of anti-thrombin III-thrombin complexes. Blood 83, 2532-2540, 1994.
9. 9. Kure, S., and Yoshie, O., A syngeneic monoclonal antibody to murine Meth-A sarcoma (HepSS-1) recognizes heparan sulfate glycosaminoglycan (HS-GAG): Cell density and transformation dependent alteration in cell surface HS-GAG defined by HepSS-1. J. Immunol. 137, 3900-3908, 1986.
10. 10. van den Born, J., van den Heuvel, J., Bakker, M. A. H., Veerkamp, J. H., Assmann, K. J. M., and Berden, J. H. M., Production and characterization of a monoclonal antibody against human glomerular heparan sulfate. Lab. Invest. 65, 287-297, 1991.
11. 11. Shibata, S., Harpel, P., Bona, C., and Fillit, H., Monoclonal antibodies to heparan sulfate inhibit the formation of thrombin-anti-thrombin III complexes. Clin. Immunol. Immunopathol. 67, 264-272, 1993.
12. 12. David, G., Bai, X. M., Van der Schueren, B., Cassiman, J. J., and Van den Berghe, H., Developmental changes in heparan sulfate expression: In situ detection with mAbs. J. Cell Biol. 119, 961-975, 1992.
13. 13. Strauss, A. H., Travassos, L. R., and Takahashi, H. K., A monoclonal antibody (ST-1) directed to the native heparin chain. Anal. Biochem. 201, 1-8, 1992.
14. 14. Huhle, G., Harenberg, J., Malsch, R., and Heene, D. L., Comparison of three heparin bovine serum albumin binding methods for production of antiheparin antibodies. Semin. Thromb. Hemost. 20, 193-204, 1994.
15. 15. Pejler, G., Lindahl, U., Larm, E., Scholander, E., Sandgren, E., and Lundblad, A., Monoclonal antibodies specific for oligosaccharides prepared by partial nitrous acid deamination of heparin. J. Biol. Chem. 263, 5197, 1988.
16. 16. Shibata, S., Sasaki, T., Harpel, P., and Fillit, H., Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin. Immunol. Immunopathol. 70, 114-123, 1994.
17. 17. Adams, J. G., Humphrey, L. J., Zhang, X., and Silver, D., Do patients with the heparin-induced thrombocytopenia syndrome have heparin-specific antibodies? J. Vasc. Surg. 21, 247, 1995.
18. 18. Visentin, G. P., Ford, S. E., Scott, J. P., and Aster, R. H., Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93, 81-88, 1994.
19. 19. Amiral, J., Bridey, F., Wolf, M., Boyer-Neumann, C., Fressinaud, E., Vissac, A. M., Peynaud-Debayle, E., Dreyfus, M., and Meyer, D., Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb. Haemost. 73, 21, 1995.
20. 20. Santoro, S., Antiphospholipid antibodies and thrombotic predisposition: Underlying pathogenetic mechanisms. Blood 83, 2389, 1994.
21. 21. Roubey, R. A. S., Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "anti-phospholipid" autoantibodies. Blood 84, 2854, 1994.
22. 22. Kashihara, N., Makino, H., Szekanecz, Z., Waltenbaugh, C. R., and Kanwar, Y. S., Nephritogenicity of anti-proteoglycan antibodies in experimental murine lupus nephritis. Lab. Invest. 67, 752-760, 1992.
23. 23. Miettinen, A., Stow, J. L., Mentone, S., and Farquhar, M. G., Antibodies to basement membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening. J. Exp. Med. 163, 1064-1084, 1986.
24. 24. Abrass, C. K., and Cohen, A. H., Characterization of renal injury initiated by immunization of rats with heparan sulfate. Am. J. Pathol. 130, 103-111, 1988.
25. 25. Faaber, P., Rijke, T. P. M., van de Putte, L. B. A., Capel, P. J. A., and Berden, J. H. M., Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycocsoaminoglycan in glomerular basement membrane. J. Clin. Invest. 77, 1824-1830, 1986.
26. 26. Naparstek, Y., Ben-Yehuda, A., Madaio, M. P., Bar-Tana, R., Schuger, L., Pizov, G., Neeman, Z., and Cohen, I. R., Heparin neutralizes nephritogenic autoantibodies in systemic lupus erythematosus. Arth. Rheum. 33, 1554-1559, 1991.
27. 27. Theofilopoulos, A. N., and Dixon, F. J., Murine models of systemic lupus erythematosus. Adv. Immunol. 37, 269, 1985.
28. 28. Lindahl, U., Lidholt, K., Spillmann, D., and Kjellen, L., More to "heparin" than anticoagulation. Thromb. Res. 75, 1-32, 1994.
29. 29. Dawes, J., Measurement of the affinities of heparins, naturally occurring glycosaminoglycans, and other sulfated polymers for antithrombin III and thrombin. Anal. Biochem. 174, 177, 1988.
30. 30. Jordan, R. E., Beeler, D., and Rosenberg, R. D., Fractionation of low molecular weight heparin species and their interaction with antithrombin. J. Biol. Chem. 254, 2902, 1979.
31. 31. Brinkman, K., Termaat, R., Berden, J. J. M., and Smeenk, R. J. T., Anti-DNA antibodies and lupus nephritis: The complexity of cross-reactivity. Immunol. Today 11, 232-234, 1990.
32. 32. Ricketts, C. R., Dextran sulfate - A synthetic analogue of heparin. Biochem. J. 51, 129, 1952.
33. 33. Dimitriu-Bona, A., and Fillit, H., Studies of the cellular immune response to heparan sulfate proteoglycan in the Tight Skin mouse. Cell. Immunol. 150, 321-332, 1993.
34. 34. Greinacher, A., Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in the pathogenesis. Semin. Thromb. Hemost. 21, 106, 1995.
35. 35. Scatchard, G., The attractions of proteins for small molecules and anions. Ann. N. Y. Acad. Sci. 51, 660, 1949.